Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence



Rating:

Share or cite this content

Citations should be made in the following way:
S. Baldi (Parma, Italy), O. Usmani (London, United Kingdom), S. Warren (Cardiff, United Kingdom), I. Panni (Parma, Italy), L. Girardello (Verona, Italy), F. Rony (Parma, Italy), G. Taylor (Cardiff, United Kingdom), W. De Backer (Antwerp, Belgium), G. Georges (Parma, Italy). Lung deposition and distribution of inhaled extra fine beclomethasone dipropionate / formoterol fumarate /glycopyrronium bromide (BDP/FF/GB) in subjects with and without airflow obstruction.. 3396

Member's Comments

No comment yet.

Related content which might interest you: Lung deposition of the extrafine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005 Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma Year: 2007 Extrafine glycopyrronium bromide (GB) in addition to extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FF) in uncontrolled asthmatic patients Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Reduction in air trapping and dyspnea with an extrafine combination of beclomethasone and formoterol in COPD Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Systemic activity of inhaled beclomethasone dipropionate HFA: a comparison of volume spacers Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Effect of hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) on small airways involvement in asthma: assessment using impulse oscillometry system (IOS) Source: Eur Respir J 2007; 30: Suppl. 51, 352s Year: 2007 A comparison of salmeterol xinafoate (SX) plus beclomethasone dipropionate (BDP) and theophylline (Theo) plus BDP in the treatment of moderate chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005 Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler® Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Acceptability and efficacy of beclomethasone dipropionate (Béclojet HFA®) and fluticasone dipropionate (Flixotide HFA®, FDP) associated with the Volumatic® spacer in adults with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003 Lung deposition of formoterol in COPD patients: comparison of formoterol HFA pMDI, and formoterol dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 100s Year: 2007 Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002 Protective effect of inhaled beclomethasone dipropionate (BDP) in asthmatic patients with exercise-induced bronchoconstriction (EIB) Source: Eur Respir J 2002; 20: Suppl. 38, 306s Year: 2002 A superior improvement in lung function in patients with moderate persistent asthma is seen with mometasone furoate 200 μg b.i.d delivered by dry powder inhaler compared with beclomethasone dipropionate 168 μg Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001 Montelukast plus inhaled budesonide versus double dose inhaled budesonide in nonasthmatic eosinophilic bronchitis Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study. Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020 Comparison of the anti-inflammatory effects of extra-fine HFA-beclomethasone (BDP) versus fluticasone (FP)-DPI on inflammatory markers in exhaled breath in childhood asthma Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up Year: 2007 QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009 Efficiency of extrafine beclometasone dipropionat/formoterol fumarate in asthma patients with cold and/or osmotic airway hyperresponsiveness (AHR) Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Vascular remodelling and inhaled beclomethasone dipropionate in COPD patients Source: Eur Respir J 2007; 30: Suppl. 51, 598s Year: 2007